Plain-English translation of NCT07470151 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is an early-stage clinical trial testing EVM18001, a new injectable medication designed to help people whose lupus, myasthenia gravis, or scleroderma has not improved with standard treatments. Researchers want to learn if the medication is safe, what dose works best, and whether it can reduce disease activity in people with these hard-to-treat autoimmune conditions. About 12 people will receive multiple doses of the treatment and be closely monitored.
People with lupus, myasthenia gravis, and scleroderma sometimes do not respond well to standard medications—their disease stays active despite treatment. This trial exists to explore whether this new medication could help those people by working in a different way than existing therapies.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive multiple injections of the medication according to a dose schedule assigned by the research team. You will attend several visits to the hospital for blood tests, health assessments, and monitoring for any side effects. It is important that you tell your study doctor right away if you experience any new symptoms, schedule conflicts, or changes in your other medications. The study also requires you to use effective birth control during treatment and for 12 months after your last injection.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
China